Psychedelic drugs may help alleviate symptoms of depression, scientists suggest
Published 03/07/2014 | 11:59
The Beatles wrote songs about them and Aldous Huxley said they could be “extremely good for anybody with fixed ideas”. Now scientists are beginning to understand exactly what happens to our brain under the influence of psychedelic drugs, revealing intriguing insights into their well-observed link to creativity.
In a new analysis of a study which saw 15 volunteers undergo magnetic resonance imaging (MRI) scans while under the influence of psilocybin, the active ingredient of magic mushrooms, scientists have discovered that the patterns of activity seen in their brains bore “fascinating” similarities to those seen when dreaming.
The researchers found that while activity in parts of the brain responsible for high level thinking such as planning and analysing was “disjointed and uncoordinated”, activity in more primitive areas of the brain associated with emotional thinking was much more pronounced.
They also saw that different areas of the brain were able to communicate in “novel” ways, giving the study volunteers a much larger range of potential brain states: something the researchers said could be a physical counterpart to the sensation of “mind expansion” often reported by users of psychedelics such as magic mushrooms, LSD and mescaline.
The study is published in the journal Human Brain Mapping today.
Aldous Huxley, when describing the experience of taking mescaline in his 1954 book The Doors of Perception, said that the experience was like “seeing what Adam saw on the morning of his creation”, and recalled in great detail the “labyrinth of endlessly significant complexity” visible even in the folds of his trousers. He said that the people who could gain most from taking LSD were “professors” because of the insights it could offer.
Scientists at Imperial College are currently researching whether psilocybin may help alleviate symptoms of depression.
Dr Robin Carhart-Harris, from Imperial’s department of medicine, said that the observed ability of psychedelics to give users a level of “emotional insight” was a strong argument for their use in psychotherapy, adding that they may even have a useful role in creative problem solving.
“There may be something in the loosening of the mind that occurs both in dreaming and in the psychedelic state that could be useful in terms of facilitating creative insight,” he said, adding that the scans showed that psychedelics could promote “a more exploratory kind of thinking”.
“Novel connections are made between different ideas and different topics,” he said. “There’s a fluidity and fluency to cognition. Only now are we forming ideas about what that might rest on in terms of changes in brain activity.”
A similar effect may be at work in forming the hallucinations and heightened perception of colour and pattern associated with a psychedelic trip.
“Much of what the brain does when we experience the world is to make predictions,” Dr Carhart-Harris said. “The brain gets quite adept at this and the world becomes more and more familiar and less surprising. Our predictions and our assumptions about the world begin firm up and we experience the world with assurance and confidence.
“What appears to happen with psychedelics is that process goes awry and the brain makes impetuous inferences about the world: this might be the basis of hallucinations. For instance, usually you look at the trunk of a tree and see the trunk of a tree. But on a psychedelic drug we may see a face in the trunk. It may be that the modules of the brain that normally process faces has ‘broken free’ and is making inferences in an impetuous way where there is no sensory evidence to call it up.”
Magic mushrooms are Class A drugs, but Dr Carhart-Harris said that any therapeutic use of psychedelics could be safe if appropriate cautions over dose and environment were observed.